M. A. Nikitina

M. A. Nikitina

Auto-generated profile, based on publicly available information

M. A. Nikitina

Siberian State Medical University

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2024 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
MNM.A. Nikitina
M.A. Nikitina
EBElena Yu. Bragina
Elena Yu. Bragina
NMNazarenko Maria
Nazarenko Maria
LLLyudmila Levchuk
Lyudmila Levchuk
SISvetlana Ivanova
Svetlana Ivanova
VAV.M. Alifirova
V.M. Alifirova
OBJECTIVE To evaluate the clinical features and the level of serum brain-derived neurotrophic factor (BDNF) in groups of patients with Parkinson’s disease (PD) differentiated by the genotypes of BDNF polymorphism (rs6265). MATERIAL AND METHODS The level of serum BDNF in the biomarkers’ multiplex panel of neurodegenerative diseases (HNDG3MAG-36K) was assessed in 134 PD patients. Allele discrimination was carried out by real-time PCR using TaqMan probes for the analysis of BDNF rs6265 polymorphism in groups of patients and controls (n=192) matched for sex, age and ethnicity. RESULTS Comparing the distribution of rs6265 genotypes and alleles between groups of patients and controls no significant differences were found (p>0.05). Serum BDNF levels varied significantly by genotype (rs6265) among PD patients. Minimum mean serum BDNF level (320.1±164.6 pg/ml) was noted for individuals with the AA genotype, which significantly differs from the corresponding indicator among individuals with GA (2944.2±1590.6 pg/ml; p=0.0001) and GG genotypes (2949.4±1620.6 pg/ml; p=3.9×10–5). The concentration of BDNF significantly differed between patients with different forms of PD (p=0.0007) and increased as the stage of the disease progressed according to Hoehn and Yahr staging scale (p=1.0×10–6). CONCLUSION The BDNF rs6265 polymorphism was not associated with the development of PD in the studied population. The variability of the mean serum BDNF level was established depending on the genotype of the BDNF polymorphism in PD patients and a number of clinical features.

23 April 2024 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
MNM.A. Nikitina
M.A. Nikitina
EKEkaterina Koroleva
Ekaterina Koroleva
NBN.G. Brazovskaya
N.G. Brazovskaya
ABA.S. Boyko
A.S. Boyko
LLLyudmila Levchuk
Lyudmila Levchuk
VAV.M. Alifirova
V.M. Alifirova
OBJECTIVE To evaluate the clinical and laboratory correlation of biomarkers with anti- and pro-apoptotic activity with the severity of motor and non-motor symptoms depending on the progression rate of Parkinson’s disease (PD). MATERIAL AND METHODS A wide range of non-motor symptoms (emotional-affective, cognitive, psychotic and behavioral disorders, fatigue, sleep disorders and autonomic disorders) was evaluated using validated scales and a number of serum neuromarkers responsible for neuroplasticity and neuronal survival processes (BDNF, PDGF, cathepsin D) in 71 patients with PD (mean age 65 (55; 70) years, disease duration 7 (4; 9) years, age of onset 57 (49; 62) years). RESULTS The concentration of biomarkers (BDNF, PDGF and cathepsin D) was the lowest in the group of patients with a rapid PD progression rate (p<0.001, p=0.001 and p=0.031, respectively), the severity of motor and most non—motor symptoms was higher (p=0.023 and p=0.001, respectively) compared to middle and slow progression rate. There were correlations between BDNF concentration and the severity of depression (r=–0.63, p<0.001), apathy (r=–0.48, p<0.001), impulsive behavioral disorders (r=0.500, p<0.001), level of cognitive functions (r=0.54, p<0.001), motor symptoms (r=–0.43, p<0.001); between PDGF level and the severity of motor manifestations of PD (r=–0.30, p=0.011), depression (r=–0.70, p<0.001), apathy (r=–0.460, p<0.001), the degree of severity of behavioral disorders (r=0.742, p<0.001). No significant correlations were observed between the level of cathepsin D and the severity of clinical manifestations of PD, which indicates the connection of cathepsin D with the general pathogenesis of PD. CONCLUSION The possibility of using serum proteins of the neurotrophin subfamily and the protein associated with autophagy, cathepsin D, as biomarkers that determine the prognosis of PD, is considered.

23 April 2024 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
MNM.A. Nikitina
M.A. Nikitina
EBElena Yu. Bragina
Elena Yu. Bragina
SISvetlana Ivanova
Svetlana Ivanova
ABAnastasiia Sergeevna Boiko
Anastasiia Sergeevna Boiko
LLLyudmila Levchuk
Lyudmila Levchuk
VAV.M. Alifirova
V.M. Alifirova
Objective. To study the prevalence of chronic fatigue syndrome (CFS) and association of CFS with other clinical and neuropsychological manifestations of Parkinson’s disease (PD) as well as with serum inflammatory markers and genetic polymorphisms. Material and methods. The study included 533 patients with PD. All patients underwent clinical, neurological examination and neuropsychological testing using validated questionnaires: MoCA test, HADS, BDI-II, the Fatigue Severity Scale (FSS). Serum concentrations of inflammatory markers (slCAM-1, sVCAM-1, NCAM, CCL5, PAI-1 and MPO) were assessed in 144 patients using xMAP technology. A case-control study of CCL5 (rs2107538) and PAI-1 (rs2227631) gene polymorphisms was performed in connection with PD development and in groups differing in the presence/absence of CFS in PD. In addition, the relationship of these polymorphisms with variability in the levels of the corresponding proteins in the blood serum of patients was studied. Genotyping of CCL5 (rs2107538) and PAI-1 (rs2227631) polymorphisms was performed using real-time PCR with TaqMan probes. Results. CFS is common in 66.7% of patients in the PD group. In addition, non-motor symptoms (emotional-affective, cognitive, autonomic disorders and pain) were more common in patients with CFS. A strong correlation has been established between the severity of CFS assessed with FSS and serum concentrations of CCL5, sVCAM-1, NCAM and slCAM-1. In newly diagnosed patients with PD who were not taking antiparkinsonian drugs at the time of the study and had CFS, higher correlations were noted between inflammatory markers and the severity of CFS manifestations. When comparing the distribution of genotypes and alleles of CCL5 (rs2107538) and PAI-1 (rs2227631) polymorphisms, some differences were found between the groups of patients with PD and controls (p<0.05). However, these polymorphisms did not affect the variability of serum protein levels CCL5 and PAI-1, respectively, nor did they affect the development of CFS in patients with PD. Conclusion. CFS is common in PD, and patients with PD and CFS are characterized by elevated levels of serum markers CCL5, sVCAM-1, slCAM-1 and NCAM, suggesting the importance of the inflammatory component in the development of neurodegenerative disease. In addition, the clinical course of PD in patients with CFS is aggravated by other non-motor manifestations, including emotional-affective, cognitive, autonomic disorders and pain. These results highlight the potential contribution of an inflammatory component to the development of fatigue associated with PD, starting from the earliest clinical stages of the disease.

7 January 2021 in Bulletin of Siberian Medicine
Verified
Journal Article
Open access
PDF file
MNM. A. Nikitina
M. A. Nikitina
EBElena Yu. Bragina
Elena Yu. Bragina
NMNazarenko Maria
Nazarenko Maria
NZN. G. Zhukova
N. G. Zhukova
DGDensema Gomboeva
Densema Gomboeva
VAV. M. Alifirova
V. M. Alifirova
Атипичное течение болезни Паркинсона с клиническими проявлениями болезни Гентингтона у пациентки с аллелем 27 CAG-повторов в гене HTT

23 April 2024 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
MNM.A. Nikitina
M.A. Nikitina
EBElena Yu. Bragina
Elena Yu. Bragina
NMNazarenko Maria
Nazarenko Maria
VAV.M. Alifirova
V.M. Alifirova
Objective. To evaluate the frequency and severity of various clinical symptoms of Parkinson’s disease (PD) depending on the BDNF rs6265 polymorphism. Material and methods. The study included 533 patients with PD. The stage of PD was assessed using the Hoehn and Yahr scale (1967), motor symptoms were evaluated with MDS-UPDRS. Assessment of non-motor symptoms (NMS) in PD was conducted using the Beck Depression Inventory II (BDI-II); the Hospital Anxiety and Depression Scale (HADS); the Apathy Scale; the Montreal Cognitive Assessment (MoCA test); the Questionnaire for Impulsive-Compulsive Disorders in PD -Rating Scale (QUIP-RS). Genotyping of the BDNF variant (rs6265) was performed using real-time PCR with TaqMan probes. Results. Most PD patients have a combination of NMS increasing as the disease progresses and is determined by molecular-genetic individual characteristics. There are significant differences in the severity of motor symptoms and NMS: individuals with the AA genotype showed significantly pronounced motor symptoms (p<0.0001); emotional-affective symptoms (p<0.0001); cognitive and impulsive behavioral disorders (p<0.0001). Conclusion. The rs6265 BDNF allele A is associated with a wide range of NMS, increasing the risk of their development in patients with PD, thus playing the important role in the etiopathogenesis of this pathology.

23 March 1993 in ChemInform
Verified
Journal Article
Closed access
PDF file
AVA. A. Vasil'EV
A. A. Vasil'EV
GCG. V. Cherkaev
G. V. Cherkaev
MNM. A. Nikitina
M. A. Nikitina